Claims
- 1. A compound of the formula (I):
7
- 2. A compound of claim 1 wherein X is —CH2OH or —C(O)NR3R4.
- 3. A compound of claim 2 wherein R3 is H and R4 is (C1-C4)alkyl.
- 4. A compound of claim 1 wherein each R is H or (C1-C4)alkyl.
- 5. A compound of claim 1 wherein Z′ is —CH2— or —CH2—CH2—.
- 6. A compound of claim 5 wherein Z is —CH2— or —CH2—CH2—.
- 7. A compound of claim 1 wherein R′ comprises cyclohexyl or cyclopentyl.
- 8. A compound of claim 7 wherein X is (C1-C4)alkoxycarbonyl, C(O)NR3R4 or acetoxymethyl.
- 9. A compound of claim 7 wherein X is carboxy.
- 10. A compound of claim 7 wherein X—Z and Z′ are trans.
- 11. A compound of claim 1 wherein R is H, X is ethylaminocarbonyl, and R′ is 2(4-methoxycarbonyl-cyclohexylmethyl)ethynyl or 2-(4-carboxy-cyclohexylmethyl)ethynyl.
- 12. A compound of claim 1 wherein R is H, X is ethylaminocarbonyl, and R2 is 2-(4-acetoxymethyl-cyclohexylmethyl)ethynyl.
- 13. Methyl-4-(3-{9-[(4S,5S,2R, 3R)-5-(N-ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]-6-aminopurin-2-yl)}prop-2-ynyl)cyclohexane-carboxylate.
- 14. A therapeutic method to inhibit an inflammatory response comprising administering to a mammal in need of said therapy, an effective anti-inflammatory amount of a compound of formula (I):
8
- 15. The method of claim 14 wherein X is —CH2OH or —C(O)NR3R4.
- 16. The method of claim 15 wherein R3 is H and R4 is (C1-C4)alkyl.
- 17. The method of claim 14 wherein each R is H or (C1-C4)alkyl.
- 18. The method of claim 14 wherein Z′ is —CH2— or —CH2-CH2—.
- 19. The method of claim 17 wherein Z is —CH2— or —CH2-CH2—.
- 20. The method of claim 14 wherein R′ comprises cyclohexyl or cyclopentyl.
- 21. The method of claim 20 wherein X is (C1-C4)alkoxycarbonyl or acetoxymethyl.
- 22. The method of claim 20 wherein X is carboxy.
- 23. The method of claim 20 wherein X—Z and Z′ are trans.
- 24. A method of claim 14 wherein R is H, X is ethylaminocarbonyl and R′ is 2-(4-methoxycarbonyl-cyclohexyhnethyl)ethynyl or 2-(4-carbony-cyclohexylmethyl)ethynyl.
- 25. A method of claim 14 wherein R is H, X is ethylaminocarbonyl, and R2 is 2-(4-acetoxymethyl-cyclohexylmethyl)ethynyl.
- 26. The method of claim 14 further comprising administering a Type IV phosphodiesterase inhibitor in combination with the compound of formula (I).
- 27. The method of claim 14 wherein rolipram is administered in combination with said compound of formula (I).
- 28. The method of claim 14 wherein the inflammatory response is due to ischemia.
- 29. The method of claim 14 wherein the inflammatory response is due to atherosclerosis.
- 30. The method of claim 14 wherein the inflammatory response is due to an autoimmune disease.
- 31. The method of claim 14 wherein the inflammatory response is due to ischemia/reperfusion injury.
- 32. The method of claim 14 wherein the inflammatory response is due to stroke, traumatic brain injury, or spinal cord injury.
- 33. The method of claim 14 wherein the inflammatory response is due to organ, tissue or cell transplantation.
- 34. The method of claim 14 wherein the inflammatory response is due to infection.
- 35. The method of claim 14 wherein the inflammatory response is due to a skin disease.
- 36. The method of claim 14 wherein the inflammatory response is due to angioplasty, stent placement, shunt placement or grafting.
- 37. The method of claim 14 wherein the inflammatory response is due to an allergic disease.
- 38. The method of claim 14 wherein the inflammatory response is due to a wasting disease.
- 39. The method of claim 14 wherein the inflammatory response is due to immunosuppressive therapy.
- 40. A therapeutic composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier.
- 41. The composition of claim 37 further comprising a Type IV phosphodiesterase inhibitor.
- 42. The composition of claim 38 wherein the inhibitor is rolipram.
- 43. The composition of claim 38 wherein the carrier is a liquid carrier.
- 44. The composition of claim 43 which is adapted for parenteral administration.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of Ser. No. 09/003,930, filed Jan. 8, 1998, pending. This application claims priority of U.S. provisional patent applications Ser. Nos. 60/118,029, filed Feb. 1, 1999, and 60/124,316 filed Mar. 12, 1999.
Government Interests
[0002] The present invention was made with the assistance of U.S. Government funding (NIH Grant ROL HL37942). The U.S. Government has certain rights in this invention.
Provisional Applications (4)
|
Number |
Date |
Country |
|
60118029 |
Feb 1999 |
US |
|
60124316 |
Mar 1999 |
US |
|
60133374 |
May 1999 |
US |
|
60135573 |
May 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09333387 |
Jun 1999 |
US |
Child |
09827083 |
Apr 2001 |
US |